Calamos Advisors LLC Acquires 22,083 Shares of Celgene Co. (CELG)

Calamos Advisors LLC boosted its holdings in Celgene Co. (NASDAQ:CELG) by 2.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 808,226 shares of the biopharmaceutical company’s stock after buying an additional 22,083 shares during the period. Celgene makes up 0.9% of Calamos Advisors LLC’s investment portfolio, making the stock its 20th biggest holding. Calamos Advisors LLC owned approximately 0.10% of Celgene worth $117,856,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in CELG. Capital Counsel LLC NY grew its position in shares of Celgene by 0.4% during the 2nd quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC grew its position in shares of Celgene by 0.6% during the 2nd quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares in the last quarter. Flagship Harbor Advisors LLC grew its position in shares of Celgene by 0.9% during the 1st quarter. Flagship Harbor Advisors LLC now owns 2,054 shares of the biopharmaceutical company’s stock valued at $253,000 after purchasing an additional 18 shares in the last quarter. Savant Capital LLC grew its position in shares of Celgene by 0.9% during the 2nd quarter. Savant Capital LLC now owns 2,350 shares of the biopharmaceutical company’s stock valued at $305,000 after purchasing an additional 20 shares in the last quarter. Finally, TCI Wealth Advisors Inc. grew its position in shares of Celgene by 0.9% during the 2nd quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after purchasing an additional 26 shares in the last quarter. Institutional investors and hedge funds own 79.74% of the company’s stock.

Shares of Celgene Co. (CELG) opened at $106.97 on Wednesday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The firm has a market cap of $83,720.00, a price-to-earnings ratio of 25.23, a price-to-earnings-growth ratio of 0.82 and a beta of 1.77. Celgene Co. has a one year low of $94.55 and a one year high of $147.17.

Celgene (NASDAQ:CELG) last posted its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, topping the consensus estimate of $1.87 by $0.04. The business had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.58 earnings per share. equities analysts anticipate that Celgene Co. will post 6.68 EPS for the current fiscal year.

A number of research analysts have recently commented on CELG shares. Vetr lowered shares of Celgene from a “strong-buy” rating to a “buy” rating and set a $146.88 price target for the company. in a research report on Tuesday, August 29th. Royal Bank of Canada restated a “buy” rating and set a $173.00 price target on shares of Celgene in a research report on Thursday, October 5th. Cantor Fitzgerald restated a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Tuesday, September 26th. Robert W. Baird restated a “buy” rating and set a $162.00 price target on shares of Celgene in a research report on Thursday, September 21st. Finally, Jefferies Group restated a “buy” rating and set a $160.00 price target on shares of Celgene in a research report on Friday, September 15th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating, twenty-one have given a buy rating and one has given a strong buy rating to the stock. Celgene has a consensus rating of “Buy” and an average price target of $134.92.

ILLEGAL ACTIVITY NOTICE: “Calamos Advisors LLC Acquires 22,083 Shares of Celgene Co. (CELG)” was reported by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.com-unik.info/2017/12/27/calamos-advisors-llc-acquires-22083-shares-of-celgene-co-celg.html.

Celgene Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit